Arcturus Therapeutics – New Self-Amplifying mRNA Vaccine Approved in Japan

By Hao Liu • Friday, August 29 10:23 • Permanent Link

Meiji Seika Pharma Co., Ltd. has recently received approval in Japan for a new presentation of KOSTAIVE®, a self-amplifying mRNA vaccine against COVID-19, supplied in vials containing two doses. This approval was dated August 28, and the product targets the SARS-CoV-2 Omicron sub-lineage JN.1 variant XEC.

In non-clinical studies, the vaccine was found to induce neutralizing antibodies not only against Omicron JN.1 and XEC but also against LP.8.1 and the currently circulating variants XFG and NB.1.8.1. The formulation is supplied as a two-dose vial, with one vial per carton, and the company is preparing to supply the product starting in late September 2025.

The self-amplifying mRNA vaccine is designed to provide a more durable immune response compared to standard mRNA vaccines. This is achieved by instructing the body to make more mRNA and spike protein, thereby generating a more robust immune response.

The press release did not provide specific metrics or comparisons with the previous period. Following these announcements, the company's shares moved 0.06%, and are now trading at a price of $17.30. For the full picture, make sure to review Arcturus Therapeutics's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.